Pfizer (PFE) Financials

Pfizer Inc (PFE) is an American multinational pharmaceutical corporation that is engaged in the research, development, manufacturing, and sale of prescription medicines. The company operates through various segments, including Innovative Health, Essential Health, and Pfizer Upjohn. The Innovative Health segment focuses on the discovery, development, and commercialization of medicines in various therapeutic areas, including inflammation and immunology, oncology, rare diseases, and cardiovascular and metabolic diseases. The Essential Health segment is responsible for the marketing and sale of branded generic medicines and biosimilars. Pfizer Upjohn, on the other hand, focuses on the production and sale of approved generic pharmaceutical products.

When looking at Pfizer Inc's income statement, it is important to note its key financial metrics. The company's total revenue for the latest fiscal year was $51.75 billion, with a gross profit of $30.26 billion. The earnings before interest and taxes (EBIT) were $12.32 billion, while the earnings before interest, taxes, depreciation, and amortization (EBITDA) were $14.08 billion. Pfizer Inc's net income from stockholders for the year was $9.61 billion. These figures demonstrate the company's strong financial performance and its ability to generate substantial profits.

Turning to Pfizer Inc's balance sheet, it has significant assets and liabilities. The company's total assets amount to $204.48 billion, which includes cash equivalents of $8.35 billion. On the other hand, Pfizer Inc has a total debt of $48.79 billion and total liabilities of $132.79 billion. Despite these financial obligations, the company maintains a healthy stockholders' equity of $71.69 billion. This reflects its strong financial position and the confidence investors have in its future prospects.

In terms of cash flow, Pfizer Inc has a well-managed and sustainable financial system. The company's operating cash flow for the year was $13.65 billion, which indicates its ability to generate cash from its core operations. Furthermore, Pfizer Inc's financing cash flow was $1.59 billion, highlighting its prudent approach to managing its capital structure. The company's investing cash flow was $-6.16 billion, indicating its commitment to investing in research, development, and acquisitions. Lastly, Pfizer Inc's free cash flow was $7.49 billion, demonstrating its ability to generate excess cash after meeting its operating and capital expenditure needs.

Overall, Pfizer Inc (PFE) has a solid financial foundation with robust revenue, profitability, and cash flow. The company's strong balance sheet and healthy stockholders' equity provide evidence of its financial stability. This, coupled with its strategic focus on innovation and growth, positions Pfizer Inc as a leading player in the pharmaceutical industry.

Disclaimer: This information is for informational purposes only and should not be construed as financial advice. Please consult with a qualified financial professional regarding your specific situation.